PTC Therapeutics Inc PTCT
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if PTCT is a good fit for your portfolio.
News
-
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PTC Therapeutics, Inc. - PTCT
-
CHMP Issues Negative Opinion on Translarna™ Following European Commission Request for Review
-
Interim PIVOT-HD Results Demonstrate Evidence of Favorable CNS Biomarker and Clinical Effects at Month 12 in Huntington's Disease Patients
-
PTC Therapeutics to Participate at Upcoming Investor Conference
-
PTC Therapeutics Announces Validation of Sepiapterin European MAA
-
PTC Therapeutics Announces European Commission Returns Translarna™ Opinion to CHMP For Re-evaluation
-
PTC Therapeutics Gets FDA Priority Review of Upstaza Gene Therapy
-
PTC Therapeutics Announces FDA Acceptance and Priority Review of the BLA for Upstaza™
Trading Information
- Previous Close Price
- $31.17
- Day Range
- $29.92–31.33
- 52-Week Range
- $17.53–42.63
- Bid/Ask
- $29.70 / $31.25
- Market Cap
- $2.33 Bil
- Volume/Avg
- 866,163 / 983,384
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 2.47
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
PTC Therapeutics Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of orally administered, small-molecule therapeutics. Its target area is RNA biology post-transcriptional control processes of the events occurring in a cell when an RNA messenger is copied from DNA during the transcription process. The discovered products address multiple therapeutic areas, including rare disorders, such as nonsense mutations in Duchenne muscular dystrophy and oncology.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 995
- Website
- https://www.ptcbio.com
Comparables
Valuation
|
Metric
|
PTCT
|
FOLD
|
ICPT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | — | 22.33 | 11.06 |
Price/Sales | 2.47 | 6.93 | 2.49 |
Price/Cash Flow | — | — | — |
Price/Earnings
PTCT
FOLD
ICPT
Financial Strength
|
Metric
|
PTCT
|
FOLD
|
ICPT
|
|---|---|---|---|
Quick Ratio | 1.88 | 2.22 | 3.91 |
Current Ratio | 2.03 | 3.03 | 4.22 |
Interest Coverage | −3.53 | −1.89 | −5.48 |
Quick Ratio
PTCT
FOLD
ICPT
Profitability
|
Metric
|
PTCT
|
FOLD
|
ICPT
|
|---|---|---|---|
Return on Assets (Normalized) | −17.01% | −6.98% | −5.44% |
Return on Equity (Normalized) | — | −40.42% | −33.34% |
Return on Invested Capital (Normalized) | −52.48% | −2.87% | −4.66% |
Return on Assets
PTCT
FOLD
ICPT
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk A/S ADR
NVO
| Yyglbktyb | Ytzzp | $636.9 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Sktmpvnll | Mjxvf | $122.3 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Ckzmttff | Htmwlz | $115.1 Bil | |||
| Moderna Inc
MRNA
| Zvfcbpfcr | Nhh | $44.9 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Mxdybpxfl | Pytpby | $31.3 Bil | |||
| argenx SE ADR
ARGX
| Ghvfbpmw | Wvkw | $26.2 Bil | |||
| BioNTech SE ADR
BNTX
| Gnfhvvhg | Vpc | $19.0 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Szwmsyff | Lvmqkk | $15.6 Bil | |||
| United Therapeutics Corp
UTHR
| Hfpgknc | Mdsd | $14.1 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Fjyqbmwc | Qxnhtdh | $11.7 Bil |